GB2060622A - 3-Aryl-3-aryloxyalkylamines - Google Patents
3-Aryl-3-aryloxyalkylamines Download PDFInfo
- Publication number
- GB2060622A GB2060622A GB8028715A GB8028715A GB2060622A GB 2060622 A GB2060622 A GB 2060622A GB 8028715 A GB8028715 A GB 8028715A GB 8028715 A GB8028715 A GB 8028715A GB 2060622 A GB2060622 A GB 2060622A
- Authority
- GB
- United Kingdom
- Prior art keywords
- compound
- pharmaceutically acceptable
- acid addition
- general formula
- acceptable acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/53—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and hydroxy groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/34—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/32—Oxygen atoms
Abstract
3-Aryl-3-aryloxyalkylamines of the general formula (I> <IMAGE> and their pharmaceutically acceptable acid addition salts, wherein R<1>, R<2>, R<4> and R<5> are hydrogen or lower alkyl, R<3> is hydrogen, lower alkyl or benzyl, Ar is phenyl optionally substituted by one or more halogen, trifluoromethyl, lower alkyl, lower alkoxy, nitro or amino groups, and Ar<1> is methylsulphinyl, methylsulphonyl- or cyano-substituted phenyl, 2- or 4- pyridyl, 2-pyrazinyl, 2-quinolinyl, 2- thienyl or 2-thiazolyl exhibit activity on the central nervous system, e.g. as antidepressants.
Description
SPECIFICATION 3-Aryl-3-aryloxypropylamines This invention relates to 3-aryl-3-aryloxypropylamines, to a process for preparing them, to their use and to pharmaceutical preparations containing them.
The present invention provides 3-aryl-3-aryloxypropylamines of the general formula (I)
and their pharmaceutically acceptable acid addition salts, wherein R', R2, R4 and R5 are hydrogen or lower alkyl, R3 is hydrogen, lower alkyl or benzyl, Ar is phenyl optionally substituted by one or more halogen, trifluoromethyl, lower alkyl, lower alkoxy, nitro or amino groups and Ar1 is methylsulphinyl-, methylsulphonyl- or cyano-substituted phenyl, 2- or 4-pyridyl, 2-pyrazinyl, 2-quinolinyl, 2-thienyi or 2thiazolyl.
The invention also provides process for preparing a compound of general formula (I) or a pharmaceutically acceptable acid addition salt thereof, which comprises reacting an anion of an alcohol of general formula (II)
(where Ar, R1, R2, R3, R4 and R5 are as defined above) with a halo compound of general formula (III) XAr' (Ill) [where X is fluorine and Arl is a methylsulphinyl-, methyl- sulphonyl- or cyano-substituted phenyl radical or X is fluorine, chlorine or bromine (preferably fluorine) and Ar' is 2- or 4-pyridyl, 2-pyrazinyl, 2-quinolinyl, 2-thienyl or 2-thiazolyl. The reaction may be carried out in a dipolar aprotic solvent.
Examples of dipolar aprotic solvents include dimethylsulphoxide, dimethylformamide, hexamethyiphosphoric triamide and sulpholane. Preferably the solvent is dimethylsulphoxide. The anion of the alcohol of general formula (II) is preferably formed by reacting the alcohol with potassium or sodium hydride or an alkyl or phenyl lithium (e.g. butyl lithium) in a compatible dipolar aprotic solvent. Preferably the alcohol is reacted with sodium hydride.
The process of the invention can be carried out at convenient temperatures e.g. 0 to 1000C (for example room temperature); there is generally no need to use reflux temperatures. Good yields of products are generally obtained in relatively short reaction times (e.g. within two to three hours).
If in the process described above the compound of the general formula (I) is obtained as an acid addition salt, such as a pharmaceutically acceptable acid addition salt or an acid addition salt such as an oxalate, the free base can be obtained by basifying a solution of the acid addition salt. Conversely, if the product of the process is a free base a pharmaceutically acceptable acid addition salt may be obtained by dissolving the free base in a suitable organic solvent and treating the solution with an acid, in accordance with the conventional procedures for preparing acid addition salts from base compounds.
Examples of acid addition salts are those formed from inorganic and organic acids, such as sulphuric, hydrochloric, hydrobromic, phosphoric, tartaric, fumaric, maleic, citric acetic, formic, methanesulphonic and p-toluenesulphonic acids.
Once a compound of general formula (I) is obtained, if desired it can be converted into another compound of general formula (I) methods. For example, a 3-aryl-3-aryloxypropylamine of formula (I) in which R3 and R4 are methyl can be converted to the compound in which one group is methyl and the other hydrogen by treatment with cyanogen bromide or ethyl or phenyl chloroformate followed by basic hydrolysis.
The compounds of general formula (I) possess one or more asymmetric carbon atoms, depending upon the particular substituents. The compounds can therefore exist in various stereochemical forms. It will be realised that if the starting material of formula (II) is a mixture of isomers the product of formula (I) will also be a mixture of isomers which may be separated, if required, by standard procedures. If the starting material is a single isomer then the product will also be a single isomer.
The term "lower" as used herein means that the radical referred to contains 1 to 6 carbon atoms.
The radical preferably contains 1 to 4 carbon atoms. Examples of lower alkyl radicals include methyl, ethyl, propyl and butyl. Examples of lower alkoxy radicals include methoxy, ethoxy, propoxy and butoxy.
Examples of lower alkenyl radicals include allyl and methallyl. When R1, R2 and/or R3 represent lower alkyl, the lower alkyl group is preferably a straight chain radical such as methyl, ethyl, n-propyl or nbutyl although R3 may also be, for example, a branched chain lower alkyl group such as isopropyl. R1, R2 and R5 are preferably hydrogen.
The compounds of general formula (I) and their pharmaceutically acceptable acid addition salts, including the novel compounds of the invention, generally possess pharmacological activity. In particular the compounds exhibit activity on the central nervous system, e.g. as antidepressants, as indicated by one or more of the standard pharmacological test procedures such as the reserpine hypothermia procedure based upon B. M. Askew, Life Sciences (1963), 1,725-730, the inhibition of noradrenaline or 5-hydroxytryptamine uptake in rat brain slices, the potentiation and prolongation of the effects of amphetamine and the modification of the effects of p-chloroamphetamine.For example,
N-methyl-3-(2-pyridyloxy)-3-phenylpropylamine, a representative compound of the invention, in the reserpine hypothermia procedure produced a rise in rectal temperature compared to the control of 8.70C at 10 mg/kg and 1 0.7 OC at 30 mg/kg.
The invention further provides a method of treating depression which comprises administering to a warm blooded mammal animal, particularly a human, a therapeutically effective amount of a compound of the invention. The invention also provides a pharmaceutical composition comprising a compound of the invention in association with a pharmaceutically acceptable carrier. Any suitable carrier known in the art can be used to prepare the pharmaceutical compositions. In such a composition, the carrier may be a solid, liquid or mixture of a solid and a liquid. Solid form compositions include powders, tablets and capsules. A solid carrier can be one or more substances which may also act as flavouring agents, lubricants, solubilisers, suspending agents, binders or tabletdisintegrating agents; it can also be an encapsulating material.In powders the carrier is a finely divided solid which is in admixture with the finely divided active ingredient. In tablets the active ingredient is mixed with a carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired. The powders and tablets preferably contain from 5 to 99, preferably 1080% of the active ingredient. Suitable solid carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methyl cellulose, sodium carboxymethyl cellulose, a iow melting wax, and cocoa butter. The term "composition " is intended to include the formulation of an active ingredient with encapsulating material as carrier to give a capsule in which the active ingredient (with or without other carriers) is with it. Similarly cachets are included.
Sterile liquid form compositions include sterile solutions, suspensions, emulsions, syrups and elixirs. The active ingredients can be dissolved or suspended in a pharmaceutically acceptable sterile liquid carrier, such as sterile water, sterile organic solvent or a mixture of both. Preferably a liquid carrier is one suitable for parenteral injection. Where the active ingredient is sufficiently solubie it can be dissolved in normal saline as a carrier; if it is too insoluble for this it can often be dissolved in a suitable organic solvent, for instance aqueous propylene glycol or polyethylene glycol solutions.
Aqueous propylene glycol containing from 10 to 75% of the glycol by weight is generally suitable. In other instances other compositions can be made by dispersing the fineiy-divided active ingredient in aqueous starch or sodium carboxymethyl cellulose solution, or in a suitable oil, for instance arachis oil.
Liquid pharmaceutical compositions which are sterile solutions or suspensions can be utilised by intramuscular, intraperitoneal or subcutaneous injection. In many instances a compound is orally active and can be administered orally either in liquid or solid composition form.
Preferably the pharmaceutical composition is in unit dosage form, e.g. as tablets or capsules. In such form, the composition is sub-divided in unit doses containing appropriate quantities of the active ingredient; the unit dosage forms can be packaged compositions, for example packeted powders or vials or ampoules. The unit dosage form can be a capsule, cachet or tablet itself, or it can be the appropriate number of any of these in package form. The quantity of the active ingredient in a unit dose of composition may be varied or adjusted from 5 mg. or less to 500 mg. or more, according to the particular need and the activity of the active ingredient. The invention also includes the compounds in the absence of the carrier where the compounds are in unit dosage form.
The following Examples illustrate the invention.
Example 1 3-(4-Cyanophenoxy)-N,N-di methyl-3-phenylpropylamine
A mixture of N,N-dimethyl-3-hydroxy-3-phenylpropylamine (3.58 g, 20 mM), 50% sodium hydride dispersion (1 g) and DMSO (50 ml) was heated at 80" until homogeneous, cooled to ambient temperature and treated dropwise with a solution of 4-fluorobenzonitrile (2.42 g, 20 mM) in DMSO with cooling (exothermic). After 1 h the reaction mixture was poured on to water (200 ml) and extracted with ether (2x200 ml). The ether extract was extracted with 1 N hydrochloric acid (2x50 ml), the acid extract basified and then extracted with ether (2 x200 ml). The ether was dried and the solvents removed under reduced pressure to give an oil which was dissolved in ethyl acetate and treated with an excess of a solution of oxalic acid hydrate in ethyl acetate. Removal of the resultant precipitate by filtration followed by recrystallisation from ethyl acetate gave the title compound (4.8 g) as the oxalate quarter hydrate m.p. 800 (decomp).
Found: C, 64.1; H, 6.05; N, 7.7% C18H20N2O . C2H204 requires: C, 64.1; H, 6.1; N 7.5%
Example 2 3-(4-Cyanophenoxy)-N-methyl-3-phenylpro pylam ine
A mixture of 3-hydroxy-N-methyl-3-phenylpropylamine (2.5 g, 1 5 mM), 50% sodium hydride dispersion (750mg) and DMSO (50 ml) were heated at 800 until homogeneous, cooled to ambient temperature and treated with a solution of 4-fluorobenzonitrile (1.82 g, 15 mM) in DMSO (10 ml).
After 1 h the mixture was poured on to water (250 ml) and extracted with ether (2x250 ml). The combined ether layers were extracted wi:h 2N hydrochloric acid (2x25 ml), the acid extracts basified and extracted with ether (2x 100 ml). The organic phase was dried, evaporated and the residue dissolved in ethyl acetate. Treatment with an excess of a solution of oxalic acid in ethyl acetate gave the title compound as the oxalate (3 g) m.p. 13130.
Found: C, 64.0; H, 5.9; N 8.0% C17H18N2O . C2H204 requires: C. 64.0; H, 5.7; N, 7.9%.
Example 3 N,N-Dimethyl-3-(2-pyridyloxy)-3-phenylpropylamine A mixture of N,N-dimethyl-3-hydroxy-3-phenylpropylamine (4.48 g, 25 mM), prewashed 50% sodium hydride (1.25 g, 25 mM) and DMSO (50 ml) was maintained at 800 until homogenous, cooled to ambient temperature and treated with a solution of 2-fluoropyridine (2.72 g, 25 mM) in DMSO (10 ml). After 1 h the mixture was poured on to water (250 ml) and extracted with ether (2x250 ml). The combined organic extracts were washed with brine, dried and evaporated. The residue was dissolved in ethyl acetate and added to an excess of a solution of oxalic acid dihydrate in ethyl acetate. Removal of the resulting precipitate by filtration followed by drying in vacuo gave the title compound as the oxalate quarter hydrate (5.8 g) m.p. 133--50.
Found: C, 61.6; H, 6.5; N, 7.8% C,8H22N205. TH2O requires: C, 61.6; H, 6.5; N, 8.0%.
Example 4
N-Methyl-3-(2-pyridyloxy)-3-phenylpropylamine
A mixture of 3-hydroxy-N-methyl-3-phenylpropylamine (4.1 g, 25 mM), prewashed 50% sodium hydride (1.25 g, 25 MM) and DMSO (50 ml) was obtained at 800 until homogeneous, cooled to ambient temperature and treated with a solution of 2-fluoropyridine (2.72 g, 25 mM) in DMSO (10 ml).
After 1 h the mixture was poured on to water (250 ml) and extracted with ether (2 x250 ml). The combined organic extracts were washed with brine, dried and evaporated. The residue was dissolved in ethyl acetate and added to an excess of a solution of oxalic acid in ethyl acetate. The resultant precipitate was removed by filtration and dried in vacuo to give the title compound as the oxalate (5.5 g) m.p. 161--30 (decomp.).
Found: C,61.1; H, 6.2; N, 8.3% C1sH18N2O . C2H204 requires: C, 61.4; H, 6.1; N, 8.4%.
Example 5 N,N-Dimethyl-3-(4-methylsulphinylphenoxy)-3-phenylpropylamine A mixture of N,N-dimethyl-3-hydroxy-3-phehylpropylamine (3.58 g, 20 mM), 50% sodium hydride dispersion (1 g) and DMSO (50 ml) was heated at 800 until homogeneous, cooled to room temperature and treated dropwise with a solution of 1-fluoro-4-methylsulphinylbenzene (3.16 g, 20 mM) in DMSO (10 ml) (slightly exothermic). After 2 hours the reaction mixture was poured onto water (200 ml) and extracted with ether (2 x200 ml). The ether layer was extracted with 1 N hydrochloric acid (2x50 ml), the extracts basified, extracted with ether (2x200 ml).The final ether extracts were dried, and the solvent removed under reduced pressure to give an oil which was taken up in ethyl acetate (250 ml) and treated with a solution of oxalic acid hydrate (3 g) in ethyl acetate (250 ml). Removal of the resultant precipitate by filtration and drying in vacuo gave the title compound as the oxalate hemihydrate (6.3 g), m.p. 110--1120.
Found: C, 57.75; H, 6.45; N, 3.2% Cj8H23NO2S . C2H204. TH2O required: C, 57.7; H, 6.3; N, 3.4%.
Example 6 N,N-Dimethyl-3-(4-methylsulphonylphenoxy)-3-phenylpropyla mine
A mixture of N,N-dimethyl-3-hydroxy-3-phenylpropylamine (3.58 g, 20 mM) 50% sodium hydride dispersion (1 g) and DMSO (50 ml) was heated at 800 until homogenous, cooled to ambient temperature and treated dropwise with a solution of 1-fluoro-4-methylsulphonylbenzene (3.48 g, 20
mM) in DMSO (10 ml) (slightly exothermic). After 1 hour the reaction mixture was poured onto water (200 ml) and extracted with ether (2 x200 ml). The ether extract was extracted with 1 N hydrochloric acid (2x50 ml), the acid layer basified and extracted with ether (2x200 ml). The ether layer was dried, the solvents removed under reduced pressure, the residue dissolved in ethyl acetate and treated with an excess of a solution of oxalic acid in ethyl acetate.Removal of the resultant precipitate by filtration followed by recrystallisation from acetone gave the title compound as the oxalate (4.5 g), m.p. 182- 40.
Found: C, 56.9; H, 6.25; N, 3.3% C18H23NO3S . C2H204 requires: C, 56.7; H, 6.0; N, 3.3%.
Example 7 N,N-Dimethyl-3-phenyl-3-(2-pyrazinyloxy)propylamine Following the method of Example 3, reaction of N,N-dimethyl-3-hydroxy-3-phenylpropylamine, sodium hydride and 2-chloropyrazine in DMSO gives the title compound.
Example 8 N-Methyl-3-phenyl-3-(2-quinolyloxy)propyla mine Following the method of Example 4, reaction of 3-hydroxy-N-methyl-3-phenylpropylamine, sodium hydride and 2-chloroquinoline in DMSO gives the title compound.
Example 9 N,N-Dimethyl-3-phenyl-3-(2-thiazolyloxy)propylamine Following the method of Example 3, reaction of N,N-dimethyl-3-hydroxy-3-phenylpropylamine, sodium hydride and 2-bromothiazole in DMSO gives the title compound.
Example 10
N-Methyl-3-phenyl-3-(2-thienyloxy)propylamine
Following the method of Example 4, reaction of 3-hydroxy-N-methyl-3-phenylpropylamine, sodium hydride and 2-fluorothiophen in DMSO gives the title compound.
Example 11
N,N-Dimethyl-3-(4pyridyloxy)-3-phenylprnpyla mine
A solution of the sodium salt of N,N-dimethyl-3-hydroxy-3-phenylpropylamine in DMSO is generated as in Example 3 then treated with a solution of 4-chloropyridine in ether (generated by dissolving 4-chloropyridine hydrochloride in water, adjusting the pH to 8.5 with sodium bicarbonate, extracting the aqueous solution with toluene, evaporating the toluene under reduced pressure and dissolving the residue in ether).
Aqueous work up of the reaction mixture as in Example 3 gives the title compound.
Claims (14)
1. A 3-aryl-3-aryloxypropylamine of the general formula
or a pharmaceutically acceptable acid addition salt thereof wherein R', R2, R4 and R5 are hydrogen or lower alkyl, R3 is hydrogen, lower alkyl or benzyl, Ar is phenyl optionally substituted by one or more halogen, trifluoromethyl, lower alkyl, lower alkoxy, nitro or amino groups, and Ar' is methylsulphinyl-, methylsulphonyl- or cyano-substituted phenyl, 2- or 4- pyridyl, 2-pyrazinyl, 2-quinolinyl, 2-thienyl, or 2-thiazolyl.
2. A compound as claimed in Claim 1 wherein R5 is hydrogen.
3. A compound as claimed in Claim 1 or 2 wherein R' and R2 are both hydrogen.
4. A compound as claimed in any one of the preceding claims wherein Ar is phenyl.
5.3-(4-Cyanophenoxy)-N,N-dimethyl-3-phenylpropylamine or a pharmaceutically acceptable acid addition salt thereof.
6.3-(4-Cyanophenoxy)-N-methyl-3-phenylpropylamine or a pharmaceutically acceptable acid addition salt thereof.
7. N,N-Dimethyl-3-(2-pyridyloxy)-3-phenylpropylamine or a pharmaceutically acceptable acid addition salt thereof.
8. N-Methyl-3-(2-pyridyloxy)-3-phenylpropylamine or a pharmaceutically acceptable acid addition salt thereof.
9. A process for preparing a compound claimed in Claim 1 which comprises reacting an anion of an alcohol of general formula (II).
(where Ar, R', R2, R3, R4 and R5 are as defined in Claim 1) with a halo compound of general formula (III)
XAr' (Ill) (where X is fluorine and Art is methylsulphinyl-, methylsulphonyl- or cyano-substituted phenyl radical or X is fluorine, chlorine or bromine and Arl is 2- or 4-pyridyl, 2-pyrazinyl, 2-quinolinyl, 2-thienyl or 2thiazolyl) and, if desired converting a free base of general formula (I) into a pharmaceutically acceptable acid addition salt thereof.
10. A process as claimed in Claim 9 wherein the anion of the alcohol of general formula (II) is formed by reacting the alcohol with potassium or sodium hydride or with an alkyl or phenyl lithium.
11. A process for preparing a compound claimed in claim 1 substantially as hereinbefore described with reference to any one of the Examples.
12. A compound as claimed in Claim 1 whenever prepared by the process claimed in any one of
Claims 9 to 12.
1 3. A pharmaceutical composition comprising a compound claimed in any one of Claims 1 to 8 and 12 in association with a pharmaceutically acceptable carrier.
14. A compound claimed in any one of Claims 1 to 8 and 12 for use as an antidepressant.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB8028715A GB2060622B (en) | 1979-09-14 | 1980-09-05 | 3-aryl-3-aryloxyalkylamines |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB7932046 | 1979-09-14 | ||
| GB8028715A GB2060622B (en) | 1979-09-14 | 1980-09-05 | 3-aryl-3-aryloxyalkylamines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| GB2060622A true GB2060622A (en) | 1981-05-07 |
| GB2060622B GB2060622B (en) | 1983-05-25 |
Family
ID=26272895
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB8028715A Expired GB2060622B (en) | 1979-09-14 | 1980-09-05 | 3-aryl-3-aryloxyalkylamines |
Country Status (1)
| Country | Link |
|---|---|
| GB (1) | GB2060622B (en) |
Cited By (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0318727A2 (en) * | 1987-12-01 | 1989-06-07 | Novo Nordisk A/S | Aryloxphenylpropylamines and their preparation and use |
| JPH0285236A (en) * | 1988-04-08 | 1990-03-26 | Eli Lilly & Co | Propaneamine derivative |
| EP0576766A1 (en) * | 1992-06-29 | 1994-01-05 | Novo Nordisk A/S | Propanolamine derivatives, their preparation and use |
| WO2003011210A2 (en) * | 2001-07-31 | 2003-02-13 | Astrazeneca Ab | Arylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase |
| WO2003011830A1 (en) * | 2001-07-31 | 2003-02-13 | Astrazeneca Ab | Heteroarylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase |
| WO2003011831A1 (en) * | 2001-07-31 | 2003-02-13 | Astrazeneca Ab | Heteroarylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase |
| WO2004013082A2 (en) * | 2002-08-01 | 2004-02-12 | Basf Aktiengesellschaft | Method for producing aminoalkoxy benzylamines and aminoalkoxy benzonitriles as intermediates |
| US6887871B2 (en) | 2000-02-23 | 2005-05-03 | Astrazeneca Ab | Use of phenylheteroakylamine derivatives |
| US6900243B2 (en) | 2000-02-23 | 2005-05-31 | Astrazeneca Ab | Phenylheteroalkylamine derivatives |
| US6953797B2 (en) | 2000-02-23 | 2005-10-11 | Astrazeneca Ab | Use of phenylheteroalkylamine derivatives |
| WO2006021565A1 (en) * | 2004-08-26 | 2006-03-02 | Neurosearch A/S | Novel substituted heteroaryloxy alkylamines and their use as monoamine neurotransmitter re-uptake inhibitors |
| US7037932B2 (en) | 2001-05-18 | 2006-05-02 | Eli Lilly And Company | Heteroaryloxy 3-substituted propanamines as serotonin and norepinephrine reuptake inhibitors |
| US7410982B2 (en) | 2002-11-05 | 2008-08-12 | Eli Lilly And Company | Propanamine derivatives as serotonin and norepinephrine reuptake inhibitors |
| US7410996B2 (en) | 2002-11-05 | 2008-08-12 | Eli Lilly And Company | 3-aryloxy/thio-2,3-substituted propanamines and their use in inhibiting serotonin and norepinephrine reuptake |
| US7417064B2 (en) | 2002-11-05 | 2008-08-26 | Eli Lilly And Company | 3-aryloxy/thio-3-substituted propanamines and their use in inhibiting serotonin and norepinephrine reuptake |
| WO2008150528A1 (en) | 2007-06-04 | 2008-12-11 | Intra-Cellular Therapies, Inc. | Novel methods |
| US7488728B2 (en) | 2003-08-22 | 2009-02-10 | Eli Lilly And Company | Pyridinylmorpholine derivatives |
-
1980
- 1980-09-05 GB GB8028715A patent/GB2060622B/en not_active Expired
Cited By (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0318727A3 (en) * | 1987-12-01 | 1990-09-12 | A/S Ferrosan | Aryloxphenylpropylamines and their preparation and use |
| US5019592A (en) * | 1987-12-01 | 1991-05-28 | Novo Nordisk A/S | Aryloxyphenylpropylamines and their preparation and use |
| EP0318727A2 (en) * | 1987-12-01 | 1989-06-07 | Novo Nordisk A/S | Aryloxphenylpropylamines and their preparation and use |
| JPH0285236A (en) * | 1988-04-08 | 1990-03-26 | Eli Lilly & Co | Propaneamine derivative |
| EP0576766A1 (en) * | 1992-06-29 | 1994-01-05 | Novo Nordisk A/S | Propanolamine derivatives, their preparation and use |
| US6887871B2 (en) | 2000-02-23 | 2005-05-03 | Astrazeneca Ab | Use of phenylheteroakylamine derivatives |
| US6953797B2 (en) | 2000-02-23 | 2005-10-11 | Astrazeneca Ab | Use of phenylheteroalkylamine derivatives |
| US6900243B2 (en) | 2000-02-23 | 2005-05-31 | Astrazeneca Ab | Phenylheteroalkylamine derivatives |
| US7037932B2 (en) | 2001-05-18 | 2006-05-02 | Eli Lilly And Company | Heteroaryloxy 3-substituted propanamines as serotonin and norepinephrine reuptake inhibitors |
| WO2003011831A1 (en) * | 2001-07-31 | 2003-02-13 | Astrazeneca Ab | Heteroarylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase |
| WO2003011210A3 (en) * | 2001-07-31 | 2007-10-25 | Astrazeneca Ab | Arylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase |
| US7223794B2 (en) | 2001-07-31 | 2007-05-29 | Astrazeneca Ab | Arylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase |
| WO2003011830A1 (en) * | 2001-07-31 | 2003-02-13 | Astrazeneca Ab | Heteroarylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase |
| US7119109B2 (en) | 2001-07-31 | 2006-10-10 | Astrazeneca Ab | Heteroarylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase |
| WO2003011210A2 (en) * | 2001-07-31 | 2003-02-13 | Astrazeneca Ab | Arylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase |
| WO2004013082A3 (en) * | 2002-08-01 | 2004-07-15 | Basf Ag | Method for producing aminoalkoxy benzylamines and aminoalkoxy benzonitriles as intermediates |
| WO2004013082A2 (en) * | 2002-08-01 | 2004-02-12 | Basf Aktiengesellschaft | Method for producing aminoalkoxy benzylamines and aminoalkoxy benzonitriles as intermediates |
| US7256312B2 (en) | 2002-08-01 | 2007-08-14 | Basf Aktiengesellschaft | Method for producing aminoalkoxy benzylamines and aminoalkoxy benzonitriles as intermediates |
| US7417064B2 (en) | 2002-11-05 | 2008-08-26 | Eli Lilly And Company | 3-aryloxy/thio-3-substituted propanamines and their use in inhibiting serotonin and norepinephrine reuptake |
| US7410982B2 (en) | 2002-11-05 | 2008-08-12 | Eli Lilly And Company | Propanamine derivatives as serotonin and norepinephrine reuptake inhibitors |
| US7410996B2 (en) | 2002-11-05 | 2008-08-12 | Eli Lilly And Company | 3-aryloxy/thio-2,3-substituted propanamines and their use in inhibiting serotonin and norepinephrine reuptake |
| US7488728B2 (en) | 2003-08-22 | 2009-02-10 | Eli Lilly And Company | Pyridinylmorpholine derivatives |
| WO2006021565A1 (en) * | 2004-08-26 | 2006-03-02 | Neurosearch A/S | Novel substituted heteroaryloxy alkylamines and their use as monoamine neurotransmitter re-uptake inhibitors |
| WO2008150528A1 (en) | 2007-06-04 | 2008-12-11 | Intra-Cellular Therapies, Inc. | Novel methods |
| EP2161998A1 (en) * | 2007-06-04 | 2010-03-17 | Intra-Cellular Therapies, Inc. | Novel methods |
| JP2010529124A (en) * | 2007-06-04 | 2010-08-26 | イントラ−セルラー・セラピーズ・インコーポレイテッド | New method |
| EP2161998A4 (en) * | 2007-06-04 | 2011-01-05 | Intra Cellular Therapies Inc | Novel methods |
| US8183266B2 (en) | 2007-06-04 | 2012-05-22 | Intra-Cellular Therapies, Inc. | Methods |
Also Published As
| Publication number | Publication date |
|---|---|
| GB2060622B (en) | 1983-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2060622A (en) | 3-Aryl-3-aryloxyalkylamines | |
| SU820659A3 (en) | Method of preparing 4-amino-5-alkylsulfonyl-o-anisamide derivatives,their salts,oxides,left-and right-rotational isomers (their variations) | |
| JP2002511097A (en) | 5-HT (6) Sulfonamide derivative as a receptor antagonist and method for producing the same | |
| JPS6056143B2 (en) | Amidine derivatives and their production method | |
| GB2060618A (en) | 3-Aryl-3-Aryloxypropylamines | |
| CA1081241A (en) | Process for the preparation of phosphonous acids | |
| EP0047536B1 (en) | Substituted propylamines | |
| US4159335A (en) | Substituted anilino-2-thiazolines | |
| US4330546A (en) | 3-Aryl-3-aryloxypropylamines | |
| JP2001525399A (en) | Selective β3 adrenergic agonist | |
| NZ225430A (en) | N-aminobutyl-n-phenyl arylamides and pharmaceutical compositions | |
| US3580949A (en) | N,n'-bis-(aminoalkyl)-benzyl-amines | |
| JPS59216877A (en) | Substituted phenyl-2-(1h)-pyrimidinone | |
| SU927111A3 (en) | Process for producing oxime-esters or their salts | |
| CA1208643A (en) | 1,5-diphenyl-pyrazolin-3-one compounds, process and intermediates for preparation thereof and pharmaceutical compositions containing them | |
| AU2007338307A1 (en) | Heterocyclyl-substituted-ehylamino-phenyl derivatives, their preparation and use as medicaments | |
| GB2060620A (en) | 3-Aryl-3-aryloxypropylamines | |
| JPS60156653A (en) | Beta-phenethanol amine derivative | |
| GB2060619A (en) | 4-Aryl-4-Aryloxypiperidines | |
| US4526893A (en) | Isocarbostyril derivatives | |
| JPS6257606B2 (en) | ||
| CA1207774A (en) | 1-phenylindazol-3-one compounds, a method of preparing them and pharmaceutical compositions containing these compounds | |
| US3647802A (en) | 2-amino-4-aryl-3 4-dihydroquinolines | |
| US4162257A (en) | N,N-dimethyl-5-phenyl-2-furamides | |
| GB2060621A (en) | 3-Aryl-3-aryloxypropylamines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PE20 | Patent expired after termination of 20 years |
Effective date: 20000904 |